
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc. has demonstrated solid revenue growth across its product segments, with medical products revenue increasing by 4.7% and dental business revenue rising by 2.7%, indicating a stable demand in the healthcare market. Additionally, the Global Technology segment contributed significantly with revenues of $173 million, reflecting a robust growth of 9.7%. Furthermore, the company's adjusted EBITDA is projected to grow in the mid-single digits in 2025 compared to 2024, signaling positive expectations for ongoing profitability and operational efficiency.
Bears say
Henry Schein Inc’s disappointing gross margin of 30.7% in the latest quarter fell below the expected 31.6%, largely due to an unfavorable product mix in its distribution and specialty products sectors. Despite achieving revenue growth in both Global Specialty Products and Global Distribution segments, the overall financial outlook is clouded by higher-than-anticipated operating costs, with SG&A expenses at 24.8% of revenue, exceeding prior estimates. The divergence between actual gross margin and expectations, alongside rising expenses, reinforces a cautious view on the company's near-term profitability and operational efficiency.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares